Autolus Therapeutics/$AUTL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
- Ticker
- $AUTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 753
- Headquarters
- London, United Kingdom
- Website
- www.autolus.com
AUTL Metrics
BasicAdvanced
$341M
-
-$1.05
2.09
-
Price and volume
Market cap
$341M
Beta
2.09
52-week high
$2.58
52-week low
$1.18
Average daily volume
2M
Financial strength
Current ratio
4.886
Quick ratio
2.931
Long term debt to equity
4.665
Total debt to equity
4.915
Interest coverage (TTM)
-3.74%
Profitability
EBITDA (TTM)
-236.571
Gross margin (TTM)
-74.60%
Net profit margin (TTM)
-238.65%
Operating margin (TTM)
-210.49%
Effective tax rate (TTM)
-0.24%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-25.44%
Return on equity (TTM)
-133.00%
Valuation
Price to revenue (TTM)
2.902
Price to book
4.55
Price to tangible book (TTM)
6.05
Price to free cash flow (TTM)
-1.415
Free cash flow yield (TTM)
-70.69%
Free cash flow per share (TTM)
-0.905
Growth
Revenue change (TTM)
292.16%
Earnings per share change (TTM)
20.46%
3-year revenue growth (CAGR)
150.30%
3-year earnings per share growth (CAGR)
-2.52%
What the Analysts think about AUTL
Analyst ratings (Buy, Hold, Sell) for Autolus Therapeutics stock.
Analyst projections of the future price of Autolus Therapeutics stock.
Bulls say / Bears say
AUCATZYL sales are scaling quickly: Q2 2026 net product revenue rose 119% year on year to $45.7 million, prompting Autolus to raise its full-year revenue guidance to $140–150 million. Continued uptake at existing US centres and new centres could support further growth. (Autolus Therapeutics)
Higher volumes and manufacturing efficiencies are improving unit economics: gross margin reached 55% in Q2, up from 6% in Q1 and negative margins in 2025. If these gains continue, the company expects adult ALL gross margin to move towards 65–70%. (Autolus Therapeutics)
A July study comparing obe-cel with matched historical controls found higher remission rates and longer event-free survival than non-CAR-T standard therapies, alongside longer overall survival. The comparison was not a randomised trial, but it adds evidence that the treatment may offer a clinical advantage in adult B-ALL. (Nature)
Autolus remains loss-making despite rising sales: it reported a $110.7 million net loss in the first half of 2026, while Q2 selling, general and administrative expenses rose to $41.2 million from $30.3 million a year earlier. Commercial growth has yet to cover its operating costs. (SEC)
The Perceptive facility adds financing risk: it can provide up to $250 million, carries interest at SOFR plus 7.25%, and included warrants for 3.5 million ADSs. Debt costs and potential dilution could weigh on shareholders if revenue growth does not meet the facility’s milestones. (SEC)
Near-term commercial growth remains concentrated in the US: Autolus has put its EU launch on hold while it assesses pricing and market access, and does not expect EU sales in 2026. Early UK sales were less than 10% of US sales, limiting the contribution from that market for now. (SEC, Precision Medicine Online)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
AUTL Financial Performance
Revenues and expenses
AUTL Earnings Performance
Company profitability
Upcoming events
No upcoming events
AUTL News
AllArticlesVideos
Funds containing AUTL
Fund name | Fund size | $AUTL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.